Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4649-4667
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Figure 6 Anoctamin 5 protein expression levels in human gastric cancer tissues and a survival analysis based on anoctamin 5 expression.
A: Non-cancerous gastric epithelia were immunohistochemically stained using an anti-anoctamin 5 (ANO5) antibody. Magnification: × 100; B: Primary human gastric cancer samples were immunohistochemically stained using an anti-ANO5 antibody. Magnification: × 100; C: The immunohistochemical staining results of ANO5 are shown as intensity 0. Magnification: × 400; D: Intensity 1. Magnification: × 400; E: Intensity 2. Magnification: × 400; F: Intensity 3. Magnification: × 400; G: Gastric cancer patients were classified into two groups based on ANO5 expression: A low ANO5 expression group (< 1.3, n = 137) and high ANO5 expression group (≥ 1.3, n = 58). aP < 0.05 (significant difference). ANO5: Anoctamin 5.
- Citation: Fukami T, Shiozaki A, Kosuga T, Kudou M, Shimizu H, Ohashi T, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Morinaga Y, Konishi E, Otsuji E. Anoctamin 5 regulates the cell cycle and affects prognosis in gastric cancer. World J Gastroenterol 2022; 28(32): 4649-4667
- URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4649.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4649